NCT00000322

Brief Summary

The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions. Examine effect of tyrosine on abstinence, retention in treatment, and craving."

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Apr 1997

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 1997

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

September 20, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 21, 1999

Completed
2.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2001

Completed
Last Updated

January 12, 2017

Status Verified

April 1, 1997

First QC Date

September 20, 1999

Last Update Submit

January 11, 2017

Conditions

Amphetamine-Related Disorders

Keywords

amphetamine dependence

Outcome Measures

Primary Outcomes (4)

  • Craving

  • Drug use

  • Retention

  • Functioning

Interventions

TyrosineBEHAVIORAL

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.

You may not qualify if:

  • No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Haight Ashbury Free Clinics

San Francisco, California, 94117, United States

Location

MeSH Terms

Conditions

Amphetamine-Related Disorders

Interventions

Tyrosine

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Amino Acids, AromaticAmino Acids, CyclicAmino AcidsAmino Acids, Peptides, and Proteins

Study Officials

  • Gantt Galloway, Pharm.D.

    Haight Ashbury Free Clinics

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

September 20, 1999

First Posted

September 21, 1999

Study Start

April 1, 1997

Study Completion

December 1, 2001

Last Updated

January 12, 2017

Record last verified: 1997-04

Locations

US(1)